Curaleaf is evaluating Aurora Cannabis's alternative merger agreement with Organigram while its own enhanced offer for Aurora remains active. Curaleaf criticized Aurora's board for denying due diligence, which it claims prevents a better bid and is a breach of fiduciary duty, indicating a potential bidding war or legal challenge.
Curaleaf has publicly stated it is evaluating Aurora Cannabis's new merger agreement with Organigram, while its own enhanced offer for Aurora remains on the table. This indicates a potential bidding war or a contested acquisition scenario for Aurora. Curaleaf's strong criticism of Aurora's board for denying due diligence access suggests a possible legal challenge or increased pressure on Aurora's shareholders to consider Curaleaf's offer. For traders, this creates short-term volatility for all three stocks as the outcome of the competing bids and potential board actions remain uncertain. The long-term implications depend on which deal, if any, ultimately goes through, shaping the competitive landscape of the cannabis industry.